Outset Medical, Inc. (NASDAQ:OM) CEO Sells $16,643.00 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 935 shares of the business’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $17.80, for a total value of $16,643.00. Following the completion of the transaction, the chief executive officer now directly owns 58,129 shares in the company, valued at approximately $1,034,696.20. This trade represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, February 18th, Leslie Trigg sold 974 shares of Outset Medical stock. The shares were sold at an average price of $13.50, for a total transaction of $13,149.00.

Outset Medical Trading Down 0.3%

NASDAQ OM opened at $19.50 on Monday. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12. Outset Medical, Inc. has a 52 week low of $5.85 and a 52 week high of $72.60. The business has a 50 day moving average price of $11.57 and a 200-day moving average price of $12.84. The company has a market cap of $70.10 million, a price-to-earnings ratio of -7.86 and a beta of 1.90.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($3.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($2.69). Outset Medical had a negative net margin of 112.57% and a negative return on equity of 175.64%. The business had revenue of $29.75 million for the quarter, compared to the consensus estimate of $27.81 million. As a group, equities analysts expect that Outset Medical, Inc. will post -1.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Outset Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. Woodline Partners LP bought a new stake in Outset Medical during the first quarter worth $14,663,000. Parkman Healthcare Partners LLC bought a new position in Outset Medical during the first quarter valued at about $2,556,000. Alyeska Investment Group L.P. purchased a new stake in shares of Outset Medical during the 1st quarter worth approximately $18,836,000. Durable Capital Partners LP bought a new stake in shares of Outset Medical in the 1st quarter worth approximately $19,247,000. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Outset Medical in the first quarter valued at approximately $17,730,000.

Analyst Ratings Changes

OM has been the topic of several research analyst reports. Royal Bank of Canada increased their target price on shares of Outset Medical from $12.00 to $14.00 and gave the stock a “sector perform” rating in a research note on Thursday, May 8th. Stifel Nicolaus set a $15.00 price objective on shares of Outset Medical in a research report on Friday, March 21st.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.